企业报告：2026-2030年患者与公众参与及互动计划
正文 · 中文译文
企业报告 患者与公众参与和互动计划 2026-2030 本计划阐述了MHRA在2026-2030年将实质性参与和互动置于机构工作核心的方针。 发布方： 药品和医疗保健产品监管局 发布日期： 2026年11月5日 获取有关本页面的邮件通知 文件 患者与公众参与和互动计划 2026-2030 HTML 患者与公众参与和互动计划 2026-2030 PDF，8.34 MB，24页 我们2026至2030年让患者和公众参与的计划（易读版） PDF，4.04 MB，22页 详情 药品和医疗保健产品监管局（MHRA）致力于将患者和公众置于我们工作的核心。本计划阐述了我们从2026年至2030年患者与公众参与和互动的方针。它建立在我们在《2021-2025年患者参与战略》中所取得的进展之上。 本计划说明了我们将如何让患者、照护者和更广泛的公众参与监管决策。这包括药品安全、医疗器械和新兴技术。它概述了我们包容性参与、透明和协作的原则，以及我们将如何确保更广泛的声音和经验为我们的工作提供信息。 它还阐述了我们在未来三年的优先事项和计划活动，包括： 加强伙伴关系 改善参与机会 展示患者和公众的贡献如何影响监管决策和结果 订阅邮件或打印本页 获取有关本页面的邮件通知 打印此页 探索该主题 药品、医疗器械
正文 · 英文原文
Corporate report Patient and Public Involvement and Engagement Plan 2026-2030 This plan sets out the MHRA’s approach to place meaningful involvement and engagement at the heart of the agency’s work for 2026-2030. From: Medicines and Healthcare products Regulatory Agency Published: 5 November 2026 Get emails about this page Documents Patient and Public Involvement and Engagement Plan 2026-2030 HTML Patient and Public Involvement and Engagement Plan 2026-2030 PDF, 8.34 MB, 24 pages Our plan to involve patients and the public 2026 to 2030 (easy read) PDF, 4.04 MB, 22 pages Details The Medicines and Healthcare products Regulatory Agency (MHRA) is committed to putting patients and the public at the heart of our work. This plan sets out our approach to patient and public involvement and engagement from 2026 to 2030. It builds on the progress made through our Patient Involvement Strategy 2021-2025. The plan explains how we will involve patients, carers and the wider public in regulatory decisions. This includes medicines safety, medical devices and emerging technologies. It outlines our principles for inclusive engagement, transparency and collaboration, and how we will ensure a broader range of voices and experiences inform our work. It also sets out our priorities and planned activities over the next three years, including: strengthening partnerships improving opportunities for involvement demonstrating how patient and public contributions influence regulatory decisions and outcomes Sign up for emails or print this page Get emails about this page Print this page Explore the topic Medicines, medical devices